• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Cannabis

The Psilocybin Patent Race Is On

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.
By DEBRA BORCHARDT
Mar 06, 2021 | 12:30 PM EST
Stocks quotes in this article: NMDBF, MYCOF, RVVTF, PHRRF, FTRPF, GTSIF, SHRMF

It seems that a week doesn't go by without a psychedelic company saying it has filed for a patent of some sort. This process can be confusing as the first assumption is that these companies are trying to patent a natural product. It isn't difficult to see how this misunderstanding happens. The headlines shout psychedelic company! Psilocybin! Patent! That, however, isn't exactly what is happening.

Truth Behind Psychedelic Patents

A great piece on Microdose breaks much of this down and explains the reasons why psychedelic companies are pursuing these patents. First, the plants that the medicines are based on can't be patented. Products in nature belong to the public and thus can't be patented. Microdose wrote, "One company cannot claim it as intellectual property to exclusively profit from it." However companies can "create new molecules based on natural psychedelics to create an improved drug. These new, altered molecules are patentable and provide the necessary framework to create new and focused treatments for different neurological and psychological health conditions from their natural predecessors."

If a company can get the patent, then it allows the treatment to be developed. Microdose added: "Without patents, competitors could easily duplicate the manufacturing of a drug and there would be no incentive for anyone to create these new treatments. Many of these companies are filing for provisional patents. These applications are issued by the U.S. Patent and Trademark Office (USPTO) and it helps to protect a new invention from being copied during the 12-month period before a formal patent application is filed. The idea is that it gives a company to test or refine a product before committing to the expensive and time-intensive process of a formal application."

Recent Patent Applications

Here are some of the companies that have filed for patents over the past few months, according to Psilocybin Alpha:

Earlier this week, NeonMind (NMDBF) filed for four provisional patents. Psilocybin Alpha said, "The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind's proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time." The company recently appointed pharmaceutical executive Robert Tessarolo as its President and CEO.

Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently he held the position of president and CEO of Mind Medicine (Mindmed), a psychedelic drug discovery and drug development company now traded on the NEO exchange, from September 2019 to January 2020. Prior to that, Tessarolo was headed Cipher Pharmaceuticals, a diversified specialty pharmaceutical company listed on the Toronto Stock Exchange.

In January, Mydecine (MYCOF)  filed for seven patents. Psilocybin Alpha said, "The developing patent portfolio from Mydecine is targeted at addressing the known shortcomings of psilocybin for medical uses and includes novel drug design and delivery mechanisms, precise doseable formulations and new technologies for improved use of psilocybin in a medical context" The company submitted a formal application to list its common shares on the Nasdaq. "We believe the company is entering an accelerated growth phase and the timing could not be better for listing our Shares to Nasdaq," said Josh Bartch, CEO & Chair of Mydecine.

In December, Revive Therapeutics (RVVTF) filed for a provisional patent application for "novel combinations of certain FDA approved drugs with psilocybin as a potential therapeutic option to reduce the side effects and improve the effectiveness of psilocybin to treat neurological disorders." Also in December the company said it was acquiring PharmaTher's intellectual property pertaining to psilocybin. PharmaTher is a wholly-owned subsidiary of Newscope Capital Corp. (PHRRF) , a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. The company has filed for provisional patents for psilocybin capsules, gummies, and oral strips.

In September, Field Trip (FTRPF) filed for a provisional patent described by Psilocybin Alpha as "a novel psychedelic molecule derived from the chemical structures of known psychedelic substances. FT-104 is designed to provide unique and useful pharmacological features to make a commercially viable alternative to naturally derived substances such as psilocybin, DMT and LSD. As we formulated our drug development strategy, we focused on new molecules (NCEs) that: (i) offer shorter duration of psychedelic experiences to make them more practical and convenient for use in the clinic; (ii) had similar potency to psilocybin or MDMA; (iii) had low potential for addiction; and (iv) would be simple to synthesize while differentiated and structurally distinct from psilocybin or other existing 5HT2A receptor agonists," commented Dr. Nathan Bryson, Field Trip's Chief Science Officer. "After significant research and due diligence, we initiated synthesis of a battery of small molecules, from which FT-104 was selected as our lead molecule. I am excited to take FT-104 into the next phases of our drug development program."

In September of 2020, Lobe Sciences (GTSIF) filed for three provisional patents to administer to an individual a psilocybin-derived agent and/or N-acetylcysteine via nasal delivery system, in combination with programmed virtual and augmented reality (VR, AR) simulations. In February, the company announced the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. The company said that the device design will allow for the precise control and delivery of medicines through the nasal cavity directly to the olfactory bulb for faster and more efficient uptake of psilocybin and other medicines that target the brain.

Philip Young, CEO of Lobe, said at the time that "Advancing through the initial development and testing of our innovative nasal mist device will position Lobe as the leader in the delivery of effective therapeutics to treat patients suffering from mild traumatic brain injury, post-traumatic stress disorder, and other mental health conditions. We intend to further the development of this device leading to commercialization. Completing the development of this device will enable the patients to easily treat themselves where they live and work."

In March of 2020, Champignon (SHRMF) filed for four provisional patents described by Psilocybin Alpha as a "combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD, novel delivery systems," and treatments for PTSD and OCD that are "enhanced by timely measured dosages of psilocybin and cannabidiol." The company has struggled with restating its financial filings with the Canadian Stock Exchanges and as such only the OTC shares are being traded at this time.

In more mature markets, filing for patents would be a nonevent but since psychedelics are so new, these are worth watching. There is clearly a land grab for application processes as well as formulations. While some of it feels like these companies are casting a wide net, it surely makes sense to be creative and file now at the beginning of the mushroom mania.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Debra Borchardt had no position in the securities mentioned.

TAGS: Investing | Markets | Stocks | Trading | Cannabis

More from Cannabis

Doug Kass: Cannabis Stocks Are Still Not SAFE

Doug Kass
Dec 20, 2022 11:15 AM EST

Though it is tempting, there are a host of reasons why I'm not bottom fishing.

Cannabis ETFs Could Soon Turn a New Leaf

Mark Abssy
Dec 8, 2022 1:11 PM EST

With likely passage of new legislation, the pot industry might have a remedy for the nausea it gave investors.

3 Market Sectors Are Likely to Be Most Impacted by the Midterm Election

James "Rev Shark" DePorre
Nov 8, 2022 6:22 AM EST

The focus is on positioning for the election and CPI Thursday.

I'm Monitoring a Cannabis ETF That's Showing Signs of Bottoming

Bob Byrne
Nov 7, 2022 8:04 AM EST

It's a dicey play as the price action isn't defined as yet and the ETF still could break lower.

If You're High on Tilray, Invest for the Long Term

Stephen Guilfoyle
Oct 7, 2022 11:06 AM EDT

TLRY is probably not that close to sustained profitability, but it has built the balance sheet to tough out these hard times.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:27 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login